Business
Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURNABY, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\nBURNABY, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced that Shelley McCloskey has joined the company’s leadership team as Senior Vice President, Human Resources.\n Ms. McCloskey has extensive human resources leadership experience in the life sciences and high-tech industries. Most recently, Ms. McCloskey was Vice President, Human Resources and Administration at Aquinox Pharmaceuticals, Inc. from 2015 to 2018. Previously, she was Vice President, Human Resources from 2010 to 2015 at STEMCELL Technologies Inc., Canada’s largest life sciences company by number of employees, with operations in North America, Europe and Asia Pacific. Prior to joining Stemcell, Ms. McCloskey was Vice President, Human Resources at Xantrex Technology Inc., a publicly traded global advanced renewable energy and power electronics company acquired by Schneider Electric for C$500M in 2008. From 2000 to 2005, Ms. McCloskey served as Vice President, Human Resources and Information Systems at Inex Pharmaceuticals Inc., a publicly traded biopharmaceutical company. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “I am pleased to welcome Shelley to our senior leadership team at Xenon, where she will contribute her strategic human resources skills gained over almost 20 years at companies with global, cross-border, and commercial operations in the biopharmaceutical sector. Shelley’s experience will support our continued growth as we build capabilities across the company to advance multiple, neurology-focused products in clinical development.” About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) In connection with Ms. McCloskey’s appointment, effective September 16, 2019, the Compensation Committee of the Company’s Board of Directors granted Ms. McC...